Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation of sonelokimab from competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75, nearly 90%, from $61.99 to $6.24 per share [6].

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moonlake-law ...

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and certain senior executives for potential violations of federal securities laws, with a deadline for investors to join the case by December 15, 2025 [2][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [5]. Allegations and Clinical Data - The lawsuit alleges that MoonLake misrepresented its clinical data, claiming superior clinical benefits of SLK over competitors, which was not substantiated [6][7]. - The company's assertions about SLK's Nanobody structure being beneficial compared to traditional monoclonal antibodies are also called into question [6]. Stock Performance and Impact - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [8].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - The lawsuit claims that during the class period, the defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [6]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - The Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its success in securities class action settlements [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) regarding a class action lawsuit due to alleged misleading statements made by the company during a specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from March 10, 2024, to September 29, 2025, the defendants made materially false and/or misleading statements and failed to disclose critical information regarding their drug candidate SLK and its comparison to BIMZELX [1]. - Specific allegations include: 1. Both SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [1]. 2. SLK's unique Nanobody structure does not provide a clinical benefit over the traditional monoclonal structure of BIMZELX [1]. 3. The supposed increased tissue penetration of SLK does not translate to clinical efficacy [1]. 4. The defendants lacked a reasonable basis for their positive statements about SLK's superiority to monoclonal antibodies [1]. Next Steps for Shareholders - Shareholders who purchased MLTX shares during the class period are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which failed to meet its primary endpoint in a clinical study, leading to a significant drop in stock price [1][2]. Summary by Sections Allegations and Impact - The lawsuit claims that aTyr Pharma provided overly positive statements about Efzofitimod while concealing material adverse facts about its efficacy, particularly regarding the drug's ability to allow patients to taper off steroids completely [1]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, resulting in a drastic stock price decline from $6.03 to $1.02 per share, an 83.2% drop in one day [1]. Class Action Details - Shareholders who purchased shares during the class period from November 7, 2024, to September 12, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for December 8, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle, with no cost or obligation to participate [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Molina Healthcare, Inc. regarding a class action lawsuit due to alleged false statements and material omissions that negatively impacted the company's stock price [1]. Summary by Sections Allegations - Defendants allegedly made false statements and concealed material adverse facts about Molina's "medical cost trend assumptions" [1]. - It was claimed that Molina was facing a "dislocation between premium rates and medical cost trend" [1]. - The company's near-term growth was reportedly reliant on reduced utilization of behavioral health, pharmacy, and inpatient and outpatient services [1]. - As a result of these issues, Molina's financial guidance for fiscal year 2025 was likely to be significantly reduced [1]. - The positive statements made by defendants regarding Molina's business and prospects were deemed materially misleading or lacking a reasonable basis [1]. Class Action Details - The class period for the lawsuit is from February 5, 2025, to July 23, 2025 [1]. - Shareholders are encouraged to register for the class action by December 2, 2025, to potentially be appointed as lead plaintiffs [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors affected by deceit, fraud, and illegal business practices [3]. - The firm is committed to ensuring companies engage in responsible business practices and good corporate citizenship [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that led to artificial inflation of stock prices [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1]. Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The complaint alleges that during the Class Period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Investors in Telix Pharmaceuticals Limited have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of misleading statements made by the company regarding its business operations and prospects [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that between February 21, 2025, and August 28, 2025, Telix's defendants materially overstated the progress made with prostate cancer therapeutic candidates [3]. - The complaint also claims that the quality of Telix's supply chain and partners was materially overstated, leading to misleading positive statements about the company's business [3]. - As a result of these misrepresentations, the defendants' statements lacked a reasonable basis and were materially misleading at all relevant times [3]. Group 2: Participation Information - Investors who suffered losses in Telix Pharmaceuticals are encouraged to contact the Law Offices of Howard G. Smith before January 9, 2026, to participate in the ongoing lawsuit [2][4]. - Interested parties can reach out via email, telephone, or visit the law firm's website for more information regarding their legal rights and the class action [2][4].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics for potential violations of federal securities laws, with a significant deadline for investors to act by December 15, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [3]. - Investors are encouraged to contact BFA Law for more information and to potentially lead the case [2][8]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [4]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [4]. Group 3: Allegations and Impact - The complaint alleges that MoonLake misrepresented its clinical data and the benefits of SLK's Nanobody structure compared to traditional monoclonal antibody treatments [5][6]. - Following the announcement of disappointing results from the VELA trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [7].